OBJECTIVE To explore the potential molecular mechanism of Shenlian(SL)on myocardial ischemia(MI)on the basis of network pharmacology.METHODS Firstly,the main active ingredients of SL were screened in the Traditional C...OBJECTIVE To explore the potential molecular mechanism of Shenlian(SL)on myocardial ischemia(MI)on the basis of network pharmacology.METHODS Firstly,the main active ingredients of SL were screened in the Traditional Chinese Medicine Integrated Database,and the MI-associated targets were collected from the DisGeNET database.Then,we used compound-target and target-pathway networks to uncover the therapeutic mechanisms of SL On the basis of network pharmacology analysis results,we assessed the effects of SL in MI rat model and oxygen glu⁃cose deprivation model of H9c2 cells and validated the possible molecular mechanisms of SL on myocardial injury in vivo and in vitro.RESULTS The network pharmacology results showed that 37 potential targets were recognized,including TNF-α,Bcl-2,STAT3,PI3K,and MMP2.The pathways revealed that the possible targets of SL were involved in the reg⁃ulation of inflammation and apoptosis signaling pathway.Then,in vivo experiments indicated that SL significantly reduced the myocardial infarction size of MI rats.Serum CK-MB,cTnT,CK,LDH,and AST levels were significantly decreased by SL(P<0.05 or P<0.01).In vitro,SL significantly increased H9c2 cell viability.The levels of inflammation factors including TNF-αand MMP2 were significantly decreased by SL(P<0.05 or P<0.01).TUNEL and Annexin V/propidium iodide assays indicated that SL could significantly decrease the cell apoptotic rate in vivo and in vitro(P<0.05 or P<0.01).The remarkable upregulation of anti-apoptotic Bcl-2 and downregulation of pro-apoptotic Bax protein level further confirmed this result.Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the PI3K-Akt and JAK2-STAT3 pathways were significantly enriched in SL.Compared with the model group,SL treatment significantly activated the PI3K-Akt and JAK2-STAT3 pathways in vivo and in vitro according to Western blotting analyses.CONCLU⁃SION SL could protect the myocardium from MI injury.The underlying mechanism may be related to the reduction of inflammation and apoptosis by activating the PI3K/Akt and JAK2/STAT3 pathways.展开更多
Objective: Inflammation plays a critical role in atherosclerosis, and this inflammatory reaction is being intensively studied. Shenlian Extracts (参莲提取物), an active ingredient of Chinese medicinal herbs, is believ...Objective: Inflammation plays a critical role in atherosclerosis, and this inflammatory reaction is being intensively studied. Shenlian Extracts (参莲提取物), an active ingredient of Chinese medicinal herbs, is believed to have multiple therapeutic and preventive effects against human vascular diseases, including atherosclerosis. Our work investigated whether Shenlian Extracts serves as an anti-inflammatory agent during atherogenesis. Methods: We established a model of atherosclerosis in rabbits using balloon angioplasty and a high cholesterol diet. The effects of Shenlian Extracts on vessel structure and inflammation were assessed by hematoxylin-eosin staining of the femoral artery, measurement of inflammation-related factors in serum or vascular tissue, and radioimmunoassay. Enzyme linked immunosorbent assays (ELISA), flow cytometry and western blots were also performed. Results: We show that oral pre-treatment with Shenlian Extracts suppressed the pathological changes associated with atherosclerosis and that graded doses of Shenlian Extracts reduced total serum levels of cholesterol (90, 180 and 360 mg/kg), triglyceride (180 and 360 mg/kg), and LDL-c (90, 180 mg/kg). Various doses of Shenlian Extracts reduced serum content of TNF-α (180 and 360 mg/kg), CRP (90, 180 and 360 mg/kg) and IL-8 (360 mg/kg) (P<0.05), but led to no significant changes in IL-1β levels. Treatment with Shenlian Extracts also significantly reduced VCAM-1 levels (90 and 360 mg/kg) and IGF-1 levels (90 and 180 mg/kg) in vascular tissue but had no significant effect on ICAM-1 and MCP-1 levels. Finally, Shenlian Extracts significantly reduced the abnormal expression of CD18 in monocytes in a dose-dependent manner. Conclusion: These results suggest that Shenlian Extracts may play a direct role in preventing and treating atherogenesis by inhibiting the inflammatory reaction, providing insights into the possible mechanism underlying the anti-atherosclerotic actions of Shenlian Extracts.展开更多
文摘OBJECTIVE To explore the potential molecular mechanism of Shenlian(SL)on myocardial ischemia(MI)on the basis of network pharmacology.METHODS Firstly,the main active ingredients of SL were screened in the Traditional Chinese Medicine Integrated Database,and the MI-associated targets were collected from the DisGeNET database.Then,we used compound-target and target-pathway networks to uncover the therapeutic mechanisms of SL On the basis of network pharmacology analysis results,we assessed the effects of SL in MI rat model and oxygen glu⁃cose deprivation model of H9c2 cells and validated the possible molecular mechanisms of SL on myocardial injury in vivo and in vitro.RESULTS The network pharmacology results showed that 37 potential targets were recognized,including TNF-α,Bcl-2,STAT3,PI3K,and MMP2.The pathways revealed that the possible targets of SL were involved in the reg⁃ulation of inflammation and apoptosis signaling pathway.Then,in vivo experiments indicated that SL significantly reduced the myocardial infarction size of MI rats.Serum CK-MB,cTnT,CK,LDH,and AST levels were significantly decreased by SL(P<0.05 or P<0.01).In vitro,SL significantly increased H9c2 cell viability.The levels of inflammation factors including TNF-αand MMP2 were significantly decreased by SL(P<0.05 or P<0.01).TUNEL and Annexin V/propidium iodide assays indicated that SL could significantly decrease the cell apoptotic rate in vivo and in vitro(P<0.05 or P<0.01).The remarkable upregulation of anti-apoptotic Bcl-2 and downregulation of pro-apoptotic Bax protein level further confirmed this result.Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the PI3K-Akt and JAK2-STAT3 pathways were significantly enriched in SL.Compared with the model group,SL treatment significantly activated the PI3K-Akt and JAK2-STAT3 pathways in vivo and in vitro according to Western blotting analyses.CONCLU⁃SION SL could protect the myocardium from MI injury.The underlying mechanism may be related to the reduction of inflammation and apoptosis by activating the PI3K/Akt and JAK2/STAT3 pathways.
基金supported by grants of the National Natural Science Foundation of China (30973901)the Major Program for Technique Development Research of Novel Traditional Chinese Medicine Production (2009 ZX093 01-005- 2-4)+1 种基金the Autonomous Program of China Academy of Chinese Medical Sciences (ZZ20090207)the International S&T Cooperation Project (S2011ZR0193)
文摘Objective: Inflammation plays a critical role in atherosclerosis, and this inflammatory reaction is being intensively studied. Shenlian Extracts (参莲提取物), an active ingredient of Chinese medicinal herbs, is believed to have multiple therapeutic and preventive effects against human vascular diseases, including atherosclerosis. Our work investigated whether Shenlian Extracts serves as an anti-inflammatory agent during atherogenesis. Methods: We established a model of atherosclerosis in rabbits using balloon angioplasty and a high cholesterol diet. The effects of Shenlian Extracts on vessel structure and inflammation were assessed by hematoxylin-eosin staining of the femoral artery, measurement of inflammation-related factors in serum or vascular tissue, and radioimmunoassay. Enzyme linked immunosorbent assays (ELISA), flow cytometry and western blots were also performed. Results: We show that oral pre-treatment with Shenlian Extracts suppressed the pathological changes associated with atherosclerosis and that graded doses of Shenlian Extracts reduced total serum levels of cholesterol (90, 180 and 360 mg/kg), triglyceride (180 and 360 mg/kg), and LDL-c (90, 180 mg/kg). Various doses of Shenlian Extracts reduced serum content of TNF-α (180 and 360 mg/kg), CRP (90, 180 and 360 mg/kg) and IL-8 (360 mg/kg) (P<0.05), but led to no significant changes in IL-1β levels. Treatment with Shenlian Extracts also significantly reduced VCAM-1 levels (90 and 360 mg/kg) and IGF-1 levels (90 and 180 mg/kg) in vascular tissue but had no significant effect on ICAM-1 and MCP-1 levels. Finally, Shenlian Extracts significantly reduced the abnormal expression of CD18 in monocytes in a dose-dependent manner. Conclusion: These results suggest that Shenlian Extracts may play a direct role in preventing and treating atherogenesis by inhibiting the inflammatory reaction, providing insights into the possible mechanism underlying the anti-atherosclerotic actions of Shenlian Extracts.
